Interviews

Experts discuss the CUTNETs collaborative's efforts to enhance surgical care and standardize treatment for neuroendocrine tumors across multiple centers.

AI transforms healthcare by personalizing treatment plans and enhancing patient-provider communication, revolutionizing how we approach medical care.

Pierre Gholam, MD, associate professor of medicine at Case Western Reserve University School of Medicine, discusses his approach to recognizing and managing adverse events in patients receiving tyrosine kinase inhibitors for hepatocellular carcinoma.

Rising early-onset neuroendocrine tumors reveal unique challenges and disparities, highlighting the need for tailored care and research focused on younger patients.

John L. Marshall, MD, discusses the challenges faced by oncologists in managing colorectal cancer treatments seen during a Case-Based Roundtable event.

Dr Vishal A. Patel explores critical scenarios for using cemiplimab in treating high-risk cutaneous squamous cell carcinoma, enhancing patient outcomes through tailored strategies.

Recent findings from the MIRASOL trial reveal significant advancements in treatment options for platinum-resistant ovarian cancer, emphasizing effective therapy sequencing.

Emerging research highlights the rising incidence of early-onset neuroendocrine tumors, revealing unique challenges and symptom burdens in younger patients.

Dr Vishal A. Patel discusses innovative strategies for optimizing cemiplimab in treating high-risk cutaneous squamous cell carcinoma and enhancing patient outcomes.

Dr Patel highlights the groundbreaking C-POST trial results, showcasing cemiplimab's significant impact on disease-free survival in high-risk CSCC patients.

New research compares transarterial embolization and chemoembolization for treating neuroendocrine liver metastases, revealing unexpected safety differences.

Dr Vishal A. Patel discusses the breakthrough in treating high-risk cutaneous squamous cell carcinoma with FDA-approved cemiplimab, addressing significant patient needs.

Dr Vishal A. Patel discusses the design and patient criteria for the pivotal C-POST trial evaluating adjuvant cemiplimab in high-risk cutaneous squamous cell carcinoma.

A recent study reveals that alternative donors for hematopoietic cell transplants yield similar success rates as fully matched donors, enhancing patient outcomes.

Scott Tagawa, MD, highlights the PSMAddition trial's promising results, showcasing Lutetium-177 PSMA-617's significant benefits for advanced prostate cancer treatment.

Vishal A. Patel, MD, discusses the FDA approval of cemiplimab in cutaneous squamous cell carcinoma.

Justin Watts, MD, discusses key findings from a study of olutasidenib in patients with IDH1-mutated myelodysplastic syndrome.

New trial results reveal that combining pembrolizumab and enfortumab vedotin significantly enhances survival rates in muscle-invasive bladder cancer patients.

Expert Joe DePinto analyzes the 2025 Cell and Gene Therapy Report, highlighting industry barriers and the growing role of oncologists in patient access.

Dr. Joyce O'Shaughnessy discusses the monarchE trial's findings, emphasizing the importance of abemaciclib in reducing breast cancer recurrence and improving patient access.

New findings from the monarchE trial reveal long-term benefits of abemaciclib in reducing recurrence risk for high-risk early breast cancer patients.

Petros Grivas, MD, PhD, discusses the overall survival and quality-of-life findings from the JAVELIN Bladder 100 trial of avelumab as maintenance therapy for advanced bladder cancer.

Discover how innovative spacing techniques in cancer treatment enhance radiation effectiveness while minimizing adverse effects for better patient outcomes.

A study analyzes the impact of spacers on biochemical control in prostate cancer patients, revealing significant differences in outcomes.

Dr Colette Shen discusses the promising future of NBTXR3 in cancer treatment, exploring its potential across various tumor types and ongoing trials.

Dr. Colette Shen discusses promising safety and efficacy results of NBTXR3 in treating recurrent head and neck cancer, highlighting unexpected patient responses.

Dr Colette Shen discusses the innovative Study 1100, exploring NBTXR3's safety and efficacy in treating recurrent head and neck cancer.

Binod Dhakal, MD, discusses the extended follow-up of combination selinexor in the proteasome inhibitor–naive subgroup of patients with multiple myeloma.

Researchers uncover that rectal spacers significantly enhance cancer cure rates, reducing treatment failure by 50% in prostate cancer patients.

Discover how rectal spacers revolutionize prostate cancer treatment by reducing side effects and enhancing radiation dose delivery for better patient outcomes.